Sanofi : Q3 driven by vaccines and insulin
>Strong Q3 driven by good phasing of vaccine shipments - Sanofi this morning reported its Q3 2024 results, which beat expectations in terms of both sales and core EPS, despite a very negative forex impact (-3.4% on the topline and -5.4% on the bottom line). In short, the group’s total sales came in at € 13,438m in Q3, vs € 12,634m expected (+12.3%; +15.7% at constant forex), its core EBIT at € 4,607m, vs € 4,032m expected (14.4%; 19.9% at constant forex), and its core...Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.